Insights+: The US FDA New Drug Approvals in August 2023

Shots: The US FDA approved 10 NDAs and 3 BLA in August 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 89 novel products in 2023 In August 2023, the major highlights drugs were Zurzuvae (zuranolone) approval for women with postpartum depression and Veopoz (pozelimab-bbfg) for children…

BySenior EditorSeptember 20, 2023

Insights+: The US FDA New Drug Approvals in September 2022

The US FDA approved 12 NDAs and 4 BLA in September 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 63 novel products in 2022 In September 2022, the major highlights drugs were Spevigo’s approval for generalized pustular psoriasis flares, Imfinzi for advanced biliary tract cancer, Retevmo…

BySenior EditorOctober 20, 2022

Insights+ Key Biosimilars Events of March 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Hence, the providers are more likely to adopt biosimilars as a 'reference product to biologics' possessing similar therapeutic properties The US FDA took an initiative to develop new pathways for Insulin biosimilars. Our team at PharmaShots has…

BySenior EditorApril 10, 2020

Insights+: The US FDA New Drug Approvals in September 2022

Insights+ Key Biosimilars Events of March 2020

Contact US

OUR INFORMATION

FOLLOW US